InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,105.32
(
1.13%
)
US TECH 100
17,243.20
(
1.56%
)
Dow Jones
38,260.67
(
0.46%
)
Brent Oil
88.39
(
0.27%
)
Bitcoin
63,701.58
(
-1.21%
)
Post# of 251612
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119492
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 223597

Wednesday, 05/22/2019 12:30:12 PM

Wednesday, May 22, 2019 12:30:12 PM

Post# of 251612
NVS’ QVM149* scores in phase-2 asthma trial, showing statig-better FEV1 than Advair:

https://www.globenewswire.com/news-release/2019/05/22/1840512/0/en/Novartis-phase-II-data-for-new-inhaled-combination-treatment-QVM149-demonstrates-significant-improvements-over-current-standard-of-care-inhaled-treatment.html

QVM149 is a triple-action LABA/LAMA/ICS drug administered with NVS’ proprietary Breezhaler device. The ICS component of QVM149 is licensed from MRK.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up